Retatrutide + Eloralintide Research Blend- LorettaMatch available documentation to the applicable research material and batch.
Batch documentation availableReview available analytical information for the selected research material.
Research Use Only
Laboratory Research Materials
Royal Peptides products are offered exclusively for laboratory research, analytical, and scientific applications. Not for human or veterinary use.
01Research Product Information
Royal Peptides supplies compounds intended for controlled laboratory research and analytical applications.
- For research and analytical use only
- Not intended for human consumption or administration
- Not intended for veterinary use
- Not represented as a drug, medicine, or therapeutic product
- Laboratory researchers are responsible for appropriate protocols and controls
Research Only
Laboratory Material
Analytical Use
02Lyophilized Product Format
Where applicable, Royal Peptides research materials are supplied in lyophilized form.
Lyophilization is a freeze-drying process used to remove moisture from material under controlled conditions.
- Material appearance may differ between compounds and production lots
- Lyophilized material may appear as a cake, film, or fragmented material
- The quantity of visible material may appear small relative to vial size
- Visual appearance alone does not establish identity or purity
03Storage & Laboratory Handling
Storage requirements may vary by compound, formulation, and production lot. Refer to the product label and available product-specific documentation.
- Protect research materials from excessive heat
- Limit unnecessary exposure to direct light and moisture
- Keep containers securely closed when stored
- Follow product-specific temperature requirements when provided
- Use appropriate laboratory contamination-control procedures
04Packaging & Quality Documentation
Packaging components may vary slightly between production lots. This can include vial closures, cap styles, label positioning, and external packaging.
- Check the product label and lot identifier before laboratory use
- Inspect the vial and closure for visible shipping damage
- Packaging design may differ between batches
- Lot-specific analytical documentation may be available in our COA library
ROYAL RESEARCH CATALOG
Retatrutide + Eloralintide Research Blend- Loretta
Research Material
Batch Documentation
Secure Checkout
Price per mg—
01Research focusedLaboratory research materials
02DocumentedAvailable batch information
03TrackedOrder fulfillment updates
Secure payment
VISA
link
$
₿
For laboratory and research purposes only.Not intended for human consumption, diagnostic use, therapeutic use, or administration to humans or animals.
View Documentation →
Exclusive Royal Peptides Research Blend
Loretta™ 12.5mg — Retatrutide + Eloralintide Research Blend
Loretta™ 12.5mg is an exclusive Royal Peptides premium research blend combining Retatrutide 10mg with Eloralintide 2.5mg in a single lyophilized research formulation. The blend is designed for advanced laboratory investigation of two distinct metabolic signaling compounds within one defined research material.
Retatrutide 10mg
+
Eloralintide 2.5mg
=
Loretta™ 12.5mg
Blend
Loretta™
Total Content
12.5mg
Retatrutide
10mg
Eloralintide
2.5mg
What Is Loretta™ 12.5mg?
Loretta™ is Royal Peptides' proprietary name for a dual-compound research formulation containing 10mg Retatrutide and 2.5mg Eloralintide, providing 12.5mg total research material per vial.
The formulation brings together two structurally and mechanistically distinct investigational compounds that have attracted substantial interest in modern metabolic research.
Retatrutide has been investigated as a GLP-1, GIP and glucagon receptor agonist, while Eloralintide is being investigated through a different signaling system involving the amylin receptor family.
Combining these compounds creates a defined laboratory material for researchers interested in studying the interaction of incretin, glucagon and amylin-associated signaling pathways within experimental models.
Important Research Distinction
Loretta™ is a Royal Peptides research blend. The individual
components have been investigated independently, but the Loretta™
combination should not be interpreted as an established clinical
therapy or as having demonstrated clinical efficacy as a combination.
Loretta™ Blend Composition
Each Loretta™ research vial contains a defined 4:1 ratio of Retatrutide to Eloralintide by stated mass.
Component 01
10mg
Retatrutide
+
Component 02
2.5mg
Eloralintide
Research Component 01
Retatrutide 10mg
Retatrutide, also identified in the scientific literature as LY3437943, is an investigational peptide engineered to interact with three metabolically relevant receptor systems: GLP-1, GIP and glucagon receptors.
This multi-receptor pharmacology has made Retatrutide an important research compound for investigating integrated metabolic signaling rather than a single isolated receptor pathway.
Experimental and clinical research has examined Retatrutide in relation to areas including energy-balance signaling, glucose-associated pathways, lipid metabolism and metabolic regulation.
GLP-1 Receptor
Investigated in incretin and metabolic signaling research.
GIP Receptor
Provides an additional incretin-associated signaling pathway.
Glucagon Receptor
Adds a distinct pathway relevant to energy and metabolic
research.
Research Component 02
Eloralintide 2.5mg
Eloralintide, also known by the development identifier LY3841136, is an investigational long-acting amylin receptor agonist being studied as a distinct approach to metabolic signaling research.
Amylin is a peptide hormone associated with pancreatic beta-cell biology and participates in signaling systems involved in nutrient and energy regulation.
Eloralintide is therefore scientifically distinct from the incretin/glucagon receptor pharmacology represented by Retatrutide. This difference is central to the research rationale behind examining the compounds together in a controlled laboratory environment.
Amylin Signaling
Investigated through receptor pathways distinct from the
incretin receptor family.
Metabolic Research
Studied in experimental and clinical metabolic research
programs.
Complementary Pathway
Provides a mechanistically distinct research target alongside
Retatrutide.
Why Study Retatrutide + Eloralintide?
The scientific interest in a Retatrutide and Eloralintide research blend comes from the fact that the two compounds engage different receptor systems.
Retatrutide
Multi-Receptor Signaling
Retatrutide provides a research model involving GLP-1, GIP and glucagon receptor activity.
Eloralintide
Amylin-Receptor Signaling
Eloralintide introduces a separate amylin-associated receptor pathway into the experimental model.
Loretta™ therefore provides researchers with a single defined formulation for investigating how these distinct signaling systems may interact in experimental settings.
Because combination-specific evidence may differ from evidence for either compound individually, findings involving Retatrutide alone or Eloralintide alone should not automatically be attributed to the Loretta™ blend.
Multi-Pathway Metabolic Research
Contemporary metabolic research increasingly examines communication among multiple receptor systems rather than treating individual pathways as completely isolated mechanisms.
Loretta™ combines compounds associated with four major areas of receptor research:
GLP-1
Incretin-associated receptor signaling.
GIP
Glucose-dependent insulinotropic peptide signaling.
Glucagon
Energy and metabolic signaling research.
Amylin
Distinct peptide-hormone receptor research.
Energy Balance
Experimental investigation of integrated metabolic signaling.
Pathway Interaction
Laboratory investigation of multiple signaling systems within
the same research model.
Loretta™ Research Areas
The Loretta™ formulation is intended for advanced laboratory investigation where researchers require both Retatrutide and Eloralintide within a defined research blend.
Receptor Signaling
Investigation of GLP-1, GIP, glucagon and amylin-associated receptor systems.
Metabolic Pathway Research
Experimental investigation of interconnected pathways associated with metabolic regulation.
Energy-Balance Research
Research examining signaling mechanisms associated with energy homeostasis and nutrient-response biology.
Combination Research
Controlled investigation of two mechanistically distinct compounds within a single experimental formulation.
Loretta™ 12.5mg Research Specifications
Product
Loretta™
Total Content
12.5mg
Retatrutide
10mg
Eloralintide
2.5mg
Research Ratio
4:1
Form
Lyophilized
Retatrutide Identifier
LY3437943
Eloralintide Identifier
LY3841136
Royal Peptides Exclusive
Loretta™ Premium Research Blend
Loretta™ was developed as a distinct Royal Peptides research formulation rather than simply presenting the two compounds as unrelated research materials.
Each vial provides a clearly defined 10mg Retatrutide + 2.5mg Eloralintide composition, allowing researchers to work from a consistent 12.5mg combined formulation.
Loretta™ 12.5mg FAQ
What is Loretta™ 12.5mg?
Loretta™ is an exclusive Royal Peptides research blend containing 10mg Retatrutide and 2.5mg Eloralintide, for a total stated research content of 12.5mg.
What peptides are in Loretta™?
Loretta™ contains two investigational research compounds: Retatrutide 10mg and Eloralintide 2.5mg.
What is Retatrutide?
Retatrutide, also known as LY3437943, is an investigational peptide studied for activity involving GLP-1, GIP and glucagon receptor signaling.
What is Eloralintide?
Eloralintide, also known as LY3841136, is an investigational long-acting amylin receptor agonist being studied in metabolic research.
What is the ratio of Retatrutide to Eloralintide in Loretta™?
Loretta™ contains 10mg Retatrutide and 2.5mg Eloralintide, representing a 4:1 ratio by stated mass.
Is Loretta™ the same as Retatrutide?
No. Loretta™ is a dual-compound Royal Peptides research blend. Retatrutide is one component of the formulation, with Eloralintide serving as the second component.
Has the Loretta™ combination been clinically established?
Loretta™ is a research blend. Research involving either individual component should not be interpreted as evidence establishing the safety or efficacy of this specific combined formulation.
Is Loretta™ intended for human use?
No. Loretta™ is supplied strictly as research material and is not intended for human or veterinary use.
For Research Use Only
Loretta™ 12.5mg is supplied strictly for laboratory, analytical and
research purposes. It is not intended for human or veterinary use,
consumption, diagnosis, treatment, prevention or mitigation of any
disease or medical condition. References to Retatrutide, Eloralintide,
receptors, metabolism, energy balance or other biological pathways
describe areas of scientific investigation and do not constitute
therapeutic claims. Loretta™ is a Royal Peptides research blend; data
concerning either component individually should not be interpreted as
evidence of the safety or efficacy of the combined formulation.
PRODUCT REFERENCE
Specifications
Product information pulled directly from WooCommerce.
ProductRetatrutide + Eloralintide Research Blend- Loretta
Category10-Vial Kits
Choose an option10 Vial Kit, Single Vial
DocumentationAvailable by batch
ANALYTICAL DOCUMENTATION
COA / Testing
Review available analytical documentation for the applicable product and batch.
View Analytical Documentation →Review the analytical information provided for the selected batch where available.
Keep relevant product and batch documentation with your research records.
FULFILLMENT
Shipping & Storage
Shipping options and delivery estimates are shown at checkout. Refer to the product label and applicable documentation for handling and storage information.
Complete payment using the available methods presented during checkout.
Tracking information is provided when available for the selected delivery service.
Use the product label and applicable documentation for handling and storage guidance.